Eris Lifesciences logo

ERIS - Eris Lifesciences Share Price

₹447.7 2.6  0.6%

Last Trade - 11:24am

Mid Cap
Market Cap £639.7m
Enterprise Value £624.7m
Revenue £113.7m
Position in Universe 284th / 2986
Unlock ERIS Revenue
Relative Strength (%)
1m -14.0%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -25.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
5,456 5,967 7,495 8,556 9,822 10,741 11,552 12,774 +14.5%
+26.0 +61.8 +70.2 +19.7 -1.1 +2.0 +8.80 +13.7
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 March 2020, Eris Lifesciences Ltd revenues increased 9% to RS10.74B. Net income increased 2% to RS2.96B. Revenues reflect Other operating income increase of 6% to RS158.8M. Basic Earnings per Share excluding Extraordinary Items increased from RS21.15 to RS21.60.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for ERIS
Graphical History


ERIS Revenue Unlock ERIS Revenue

Net Income

ERIS Net Income Unlock ERIS Revenue

Normalised EPS

ERIS Normalised EPS Unlock ERIS Revenue

PE Ratio Range

ERIS PE Ratio Range Unlock ERIS Revenue

Dividend Yield Range

ERIS Dividend Yield Range Unlock ERIS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ERIS EPS Forecasts Unlock ERIS Revenue
Profile Summary

Eris Lifesciences Limited is an India-based company, which is engaged in manufacturing, marketing and selling of generics within the chronic and acute categories of the Indian Pharmaceutical Market. The Company operates within various areas through its seven focused divisions: Eris, Nikkos, Adura, Montana, Inspira, Victus, Eris Kinedex, Eterna, and Altiza. Its Eris division includes Atorsave 10, Atorsave 20, Decal, Enoxsave 0.6 and Metaloc XL100 products; its Nikkos division includes Alerfix, Erinac D, Ezeepam Plus 5, Zenpride OD and Nikotriol products; its Adura division includes Crevast 5, Glitaris M30, Metafort G1 CP and Olmin 10 products; its Montana division includes Meftaris, Calshine 60K Sachet, Hinder, Rabemon 20 and Vomisave Syrup products; its Inspira division includes Crevast F 5, Lnbeta 5 and Twichek products, and its Victus division includes Atorsave D80, Cyblex M 30 XR, Cyblex M 80, Cyblex M 60 XR and Cyblex MV 40.3 products.

Last Annual March 31st, 2020
Last Interim March 31st, 2020
Incorporated January 25, 2007
Public Since June 29, 2017
No. of Shareholders: n/a
No. of Employees: 3,399
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange National Stock Exchange of India
Shares in Issue 135,780,653
Free Float (0.0%)
Eligible for
ERIS Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ERIS
Upcoming Events for ERIS
Frequently Asked Questions for Eris Lifesciences
What is the Eris Lifesciences share price?

As of 11:24am, shares in Eris Lifesciences are trading at ₹447.7, giving the company a market capitalisation of £639.7m. This share price information is delayed by 15 minutes.

How has the Eris Lifesciences share price performed this year?

Shares in Eris Lifesciences are currently trading at ₹447.7 and the price has moved by -9.51% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Eris Lifesciences price has moved by -2.59% over the past year.

What are the analyst and broker recommendations for Eris Lifesciences?

Of the analysts with advisory recommendations for Eris Lifesciences, there are there are currently 2 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Eris Lifesciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Eris Lifesciences next release its financial results?

Eris Lifesciences is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Eris Lifesciences dividend yield?

Eris Lifesciences does not currently pay a dividend.

Does Eris Lifesciences pay a dividend?

Eris Lifesciences does not currently pay a dividend.

When does Eris Lifesciences next pay dividends?

Eris Lifesciences does not currently pay a dividend.

How do I buy Eris Lifesciences shares?

To buy shares in Eris Lifesciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Eris Lifesciences?

Shares in Eris Lifesciences are currently trading at ₹447.7, giving the company a market capitalisation of £639.7m.

Where are Eris Lifesciences shares listed? Where are Eris Lifesciences shares listed?

Here are the trading details for Eris Lifesciences:

Country of listing: India
Exchange: NSI
Ticker Symbol: ERIS
What kind of share is Eris Lifesciences?

Based on an overall assessment of its quality, value and momentum, Eris Lifesciences is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Eris Lifesciences share price forecast 2020?

Shares in Eris Lifesciences are currently priced at ₹447.7. At that level they are trading at 30.85% discount to the analyst consensus target price of 0.00.

Analysts covering Eris Lifesciences currently have a consensus Earnings Per Share (EPS) forecast of 23.478 for the next financial year.

How can I tell whether the Eris Lifesciences share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Eris Lifesciences. Over the past six months, the relative strength of its shares against the market has been 2.49%. At the current price of ₹447.7, shares in Eris Lifesciences are trading at -2.64% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Eris Lifesciences PE Ratio?

The Eris Lifesciences PE ratio based on its reported earnings over the past 12 months is 20.63. The shares are currently trading at ₹447.7.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Eris Lifesciences?

Eris Lifesciences's management team is headed by:

Amit Bakshi - CHM
Inderjeet Negi - EDR
Vijaya Sampath - IND
Kirit Shelat - IND
Sanjiv Kaul - NED
Rajendrakumar Patel - OTH
Kaushal Shah - OTH
Sachin Shah - CFO
Milind Talegaonkar - CCO
Prashant Gupta - IND
Who are the major shareholders of Eris Lifesciences?

Here are the top five shareholders of Eris Lifesciences based on the size of their shareholding:

Bakshi (Amit) Individual Investor
Percentage owned: 40.28% (54.7m shares)
Shah (Rakeshbhai Bhikhabhai) Individual Investor
Percentage owned: 11.55% (15.7m shares)
Shah (Bhikhalal Chimanlal) Individual Investor
Percentage owned: 6.55% (8.89m shares)
Emerald Investments, L.P. Corporation
Percentage owned: 5.51% (7.48m shares)
Patel (Rajendrakumar Rambhai) Individual Investor
Percentage owned: 4.37% (5.94m shares)
Similar to ERIS
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.